放射性药物治疗的现状
放射性药物治疗(RPT)通过全身或局部递送放射性核素靶向肿瘤细胞,同时减少对非靶细胞的照射。当前RPT的给药活度多按固定值或体重/体表面积确定,但定量成像显示药代动力学在患者间存在差异,因此固定或按体重给药并不总能优化靶区细胞毒性剂量并满足危及器官耐受剂量。本文讨论了现代放射肿瘤学中的剂量学准确性需求、RPT剂量学不确定性以及内照射治疗成像与剂量学的最佳方法。
要点
- RPT现有给药活度多按固定值或体重/体表面积确定,未个体化优化。
- 定量成像可测量RPT药代动力学,患者间及组织间存在差异。
- 基于成像的个体化剂量学有助于提高靶区剂量准确性并减少临床试验不确定性。
核心结论
- 固定或按体重/体表面积给药的RPT活度处方目前未优化,难以在给予靶区细胞毒性剂量同时保持在危及器官耐受剂量内。
研究设计与样本
- 本文为综述性文章,讨论RPT的剂量学准确性需求、剂量学不确定性以及内照射治疗成像与剂量学的最佳方法。
主要发现
- RPT药代动力学可通过定量成像测量,且在患者间肿瘤和正常组织中存在差异。
- 目前RPT通过静脉或局部区域注射给药,治疗计划通常类似化疗,给药活度固定或基于体重/体表面积。
- 需要提供个体患者而非参考几何的剂量估计方法,以评估和调整注射RPT剂量。
关键数值与推荐
- 当前RPT示例包括131I甲状腺消融、90Y微球治疗肝癌、223Ra治疗骨转移和177Lu-DOTATATE治疗神经内分泌肿瘤。
临床怎么用
- 基于成像的剂量学方法在早期临床试验中尤为有益,可计算靶区和危及器官的个体化剂量。
- 准确的靶区和危及器官剂量将惠及个体患者并减少临床试验中的不确定性。
局限性
- 固定或按体重/体表面积给药的活度处方目前未优化,无法确保靶区细胞毒性剂量并满足危及器官耐受剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In radiopharmaceutical therapy (RPT), a radionuclide is systemically or locally delivered with the goal of targeting and delivering radiation to cancer cells while minimizing radiation exposure to untargeted cells. Examples of current RPTs include thyroid ablation with the administration of 131I, treatment of liver cancer with 90Y microspheres, the treatment of bony metastases with 223Ra, and the treatment of neuroendocrine tumors with 177Lu-DOTATATE. New RPTs are being developed where radionuclides are incorporated into systemic targeted therapies. To assure that RPT is appropriately implemented, advances in targeting need to be matched with advances in quantitative imaging and dosimetry methods. Currently, radiopharmaceutical therapy is administered by intravenous or locoregional injection, and the treatment planning has typically been implemented like chemotherapy, where the activity administered is either fixed or based on a patient's body weight or body surface area. RPT pharmacokinetics are measurable by quantitative imaging and are known to vary across patients, both in tumors and normal tissues. Therefore, fixed or weight-based activity prescriptions are not currently optimized to deliver a cytotoxic dose to targets while remaining within the tolerance dose of organs at risk. Methods that provide dose estimates to individual patients rather than to reference geometries are needed to assess and adjust the injected RPT dose. Accurate doses to targets and organs at risk will benefit the individual patients and decrease uncertainties in clinical trials. Imaging can be used to measure activity distribution in vivo, and this information can be used to determine patient-specific treatment plans where the dose to the targets and organs at risk can be calculated. The development and adoption of imaging-based dosimetry methods is particularly beneficial in early clinical trials. In this work we discuss dosimetric accuracy needs in modern radiation oncology, uncertainties in the dosimetry in RPT, and best approaches for imaging and dosimetry of internal radionuclide therapy.
引用
- St James S, Bednarz B, Benedict S, et al. Current Status of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32805300. doi:10.1016/j.ijrobp.2020.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。